Muriel Licour

1.7k total citations
27 papers, 560 citations indexed

About

Muriel Licour is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Muriel Licour has authored 27 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Muriel Licour's work include Acute Myocardial Infarction Research (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Muriel Licour is often cited by papers focused on Acute Myocardial Infarction Research (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Muriel Licour collaborates with scholars based in France, Spain and Belgium. Muriel Licour's co-authors include Lars Bastholt, Martin Schlumberger, Sophie Leboulleux, Christelle de la Fouchardière, Jan Tennvall, Ahmad Awada, Thomas Krause, José Manuel Gómez, Laurence Leenhardt and F. Bonichon and has published in prestigious journals such as Journal of the American College of Cardiology, The Lancet Oncology and European Heart Journal.

In The Last Decade

Muriel Licour

27 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Muriel Licour France	10	235	181	158	130	111	27	560
Paul H. Graham United States	14	273 1.2×	40 0.2×	151 1.0×	250 1.9×	39 0.4×	40	550
Leo A. Niemeier United States	6	118 0.5×	42 0.2×	240 1.5×	97 0.7×	109 1.0×	8	526
Inne Borel Rinkes Netherlands	12	69 0.3×	43 0.2×	163 1.0×	256 2.0×	156 1.4×	26	482
Jean-François Caubet United States	6	78 0.3×	22 0.1×	200 1.3×	51 0.4×	255 2.3×	8	473
Hideto Ito Japan	12	54 0.2×	39 0.2×	145 0.9×	170 1.3×	154 1.4×	34	401
Samuel Tekyi‐Mensah United States	10	28 0.1×	53 0.3×	52 0.3×	82 0.6×	216 1.9×	16	449
Anders Christian Larsen Denmark	12	27 0.1×	56 0.3×	176 1.1×	122 0.9×	100 0.9×	28	405
Teresa Parli United States	9	65 0.3×	27 0.1×	96 0.6×	22 0.2×	279 2.5×	20	393
Melissa Dinolfo United States	5	56 0.2×	54 0.3×	214 1.4×	56 0.4×	159 1.4×	7	363
Hiruni S. Amarasekara United States	15	17 0.1×	171 0.9×	49 0.3×	161 1.2×	475 4.3×	34	561

Countries citing papers authored by Muriel Licour

Since Specialization

Citations

This map shows the geographic impact of Muriel Licour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muriel Licour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muriel Licour more than expected).

Fields of papers citing papers by Muriel Licour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muriel Licour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muriel Licour. The network helps show where Muriel Licour may publish in the future.

Co-authorship network of co-authors of Muriel Licour

This figure shows the co-authorship network connecting the top 25 collaborators of Muriel Licour. A scholar is included among the top collaborators of Muriel Licour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muriel Licour. Muriel Licour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smit, Hans J.M., Anne Sibille, Fiona McDonald, et al.. (2021). 1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Annals of Oncology. 32. S939–S940. 15 indexed citations

McDonald, Fiona, F. Mornex, Marina Chiara Garassino, et al.. (2021). 79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Journal of Thoracic Oncology. 16(4). S738–S739. 10 indexed citations

Girard, Nicolas, Rainer Fietkau, Marina Chiara Garassino, et al.. (2020). 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Annals of Oncology. 31. S805–S806. 2 indexed citations

Girard, Nicolas, F. Mornex, Daniel C. Christoph, et al.. (2019). PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. Annals of Oncology. 30. ii37–ii37. 9 indexed citations

Marabelle, Aurélien, François Ghiringhelli, Maha Ayyoub, et al.. (2018). Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study). Annals of Oncology. 29. x10–x10. 1 indexed citations

Bueno, Héctor, Stuart Pocock, Jesús Medina, et al.. (2017). Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEACS. Revista Española de Cardiología (English Edition). 70(10). 817–824. 7 indexed citations

Pérol, M., Jean‐François Morère, Elizabeth Fabre, et al.. (2016). French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes. Annals of Oncology. 27. vi429–vi429. 1 indexed citations

Planchard, David, M. Pérol, Xavier Quantin, et al.. (2016). Osimertinib in EGFR T790M positive advanced NSCLC (aNSCLC) – real–life data from the French temporary authorization for use (ATU) program. Annals of Oncology. 27. vi427–vi427. 2 indexed citations

Silvain, Johanne, Robert F. Storey, Guillaume Cayla, et al.. (2015). IMPACT OF MORPHINE ADMINISTRATION ON TICAGRELOR-INDUCED PLATELET INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED BY PRIMARY PCI: RESULTS FROM THE PRIVATE-ATLANTIC STUDY. Journal of the American College of Cardiology. 65(10). A15–A15. 3 indexed citations

10.

Bueno, Héctor, Peter Sinnaeve, Lieven Annemans, et al.. (2015). Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. European Heart Journal Acute Cardiovascular Care. 5(1). 3–12. 33 indexed citations

11.

Pocock, Stuart, Héctor Bueno, Muriel Licour, et al.. (2014). Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study. European Heart Journal Acute Cardiovascular Care. 4(6). 509–517. 70 indexed citations

12.

Sinnaeve, Peter, Uwe Zeymer, Héctor Bueno, et al.. (2014). Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal Acute Cardiovascular Care. 4(3). 254–262. 14 indexed citations

13.

Pocock, Stuart, Héctor Bueno, Nicolas Danchin, et al.. (2013). TCT-215 Predictors of 1-year mortality at hospital discharge after ACS STEMI and NSTE-ACS: a new risk score from the EPICOR study. Journal of the American College of Cardiology. 62(18). B69–B69. 1 indexed citations

14.

Montalescot, Gilles, Jens Flensted Lassen, Christian W. Hamm, et al.. (2013). Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. American Heart Journal. 165(4). 515–522. 30 indexed citations

15.

Bueno, Héctor, Robert F. Storey, Nicolas Danchin, et al.. (2012). Current regional differences in the use of antiplatelet drugs for the treatment of acute coronary syndromes. Results from the EPICOR study. European Heart Journal. 33. 311–311. 2 indexed citations

16.

Leboulleux, Sophie, Lars Bastholt, Thomas Krause, et al.. (2012). Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology. 13(9). 897–905. 280 indexed citations

17.

Leboulleux, Sophie, Lars Bastholt, Thomas Krause, et al.. (2010). Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial. Annals of Oncology. 21. 315–315. 17 indexed citations

18.

Lablanche, Jean‐Marc, Attilio Leone, Béla Merkely, et al.. (2010). Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Archives of cardiovascular diseases. 103(3). 160–169. 20 indexed citations

19.

Lablanche, Jean‐Marc, Nicolas Danchin, Michel Farnier, et al.. (2008). Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Archives of cardiovascular diseases. 101(6). 399–406. 7 indexed citations

20.

Danchin, Nicolas, et al.. (2007). À la dose identique de 10 mg/j, la rosuvastatine est plus efficace que l'atorvastatine pour atteindre l'objectif de LDL-cholestérol < 1,00 g/l chez les patients à haut risque cardiovasculaire (étude ARIANE). Annales de Cardiologie et d Angéiologie. 56(2). 82–87. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact